MRTNZ

MRTNZ Investment Office · The 360 Vantage

DXCM · NASDAQ-GS

DexCom, Inc.

Health Care · Medical/Dental Instruments

Reference price$74.85As of Jul 28, 2026
Market capitalization$28.88B
52-week range$54.11–$89.98
QQQ portfolio weight0.13%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$64.00-14.5% vs. reference
Average$84.00+12.2% vs. reference
High$112.00+49.6% vs. reference
17 Buy1 Hold1 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportJul 30, 2026Jun 2026
Consensus EPS$0.619 estimates
Expected range$0.58–$0.64Low to high EPS
Dec 2026$2.57Street EPS consensus
Dec 2027$3.05Street EPS consensus
Dec 2028$3.63Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+15.6% YoY$4.66B$4.03B
Operating income$0.91B$0.6B
Net income$0.84B$0.58B
Operating cash flow$1.44B$0.99B
Capital expenditures($0.36B)($0.36B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends

Zacks

DXCM Q2 Results Likely to Reflect Strong G7 & Reimbursement Expansion

Zacks

Is Abbott Stock Attractive After Its Earnings and Guidance Update?

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official QQQ-tracking holdings →

Facts, estimates, and scenario analysis are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Eligibility, consensus, and price data can change. This page is illustrative research, not investment advice.